ClinicalTrials.gov
ClinicalTrials.gov Menu

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00411905
Recruitment Status : Unknown
Verified December 2006 by Groupe Francophone des Myelodysplasies.
Recruitment status was:  Recruiting
First Posted : December 15, 2006
Last Update Posted : March 12, 2007
Sponsor:
Information provided by:
Groupe Francophone des Myelodysplasies

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Primary Completion Date : No date given
  Study Completion Date : June 2006